Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | CDC25B | P30305 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2352043 | 1.00 | BLM (0.48) | BLMLMNAPTPN1FAAHALOX15 | |
| SCHEMBL2354229 | 1.00 | BLM (0.48) | BLMLMNAPTPN1FAAHALOX15 | |
| SCHEMBL2352236 | 1.00 | BLM (0.48) | BLMLMNAPTPN1FAAHALOX15 | |
| SCHEMBL4714338 | 1.00 | BLM (0.48) | BLMLMNAPTPN1FAAHALOX15 | |
| SCHEMBL2352087 | 1.00 | BLM (0.48) | BLMLMNAPTPN1FAAHALOX15 | |
| SCHEMBL3012285 | 0.98 | BLM (0.46) | BLMLMNAPTPN1FAAHALOX15 | |
| SCHEMBL11551970 | 0.98 | BLM (0.46) | BLMLMNAPTPN1FAAHALOX15 | |
| SCHEMBL11550633 | 0.87 | FAAH (0.40) | BLMPTPN1FAAHALOX15MGAM | |
| SCHEMBL13484080 | 0.87 | FAAH (0.41) | BLMLMNAFAAHALOX15MGAM | |
| SCHEMBL3780110 | 0.87 | BLM (0.50) | BLMLMNAPTPN1ALOX15CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828159-B1 | ASYMMETRIC HYDROGENATION OF ALKENES USING CHIRAL IRIDIUM COMPLEXES | DSM IP ASSETS BV (NL) | 2011-08-17 | — | — | EP | claimed |
| US-20080039638-A1 | Asymmetric Hydrogenation of Alkennes Using Chiral Iridium Complexes | DSM IP ASSETS B.V. (NL) | 2008-02-14 | — | — | US | claimed |
| EP-1828159-A1 | ASYMMETRIC HYDROGENATION OF ALKENES USING CHIRAL IRIDIUM COMPLEXES | DSMIP Assets B.V. (NL) | 2007-09-05 | — | — | EP | claimed |
| WO-2006066863-A1 | ASYMMETRIC HYDROGENATION OF ALKENNES USING CHIRAL IRIDIUM COMPLEXES | DSM IP ASSETS B.V. (NL) | 2006-06-29 | — | — | WO | claimed |
| US-8426617-B2 | Asymmetric hydrogenation of alkenes using chiral iridium complexes | DSM IP ASSETS B.V. (NL) | 2013-04-23 | — | — | US | disclosed |
| EP-1828159-B1 | ASYMMETRIC HYDROGENATION OF ALKENES USING CHIRAL IRIDIUM COMPLEXES | DSM IP ASSETS BV (NL) | 2011-08-17 | — | — | EP | disclosed |
| US-20080039638-A1 | Asymmetric Hydrogenation of Alkennes Using Chiral Iridium Complexes | DSM IP ASSETS B.V. (NL) | 2008-02-14 | — | — | US | disclosed |
| EP-1828159-A1 | ASYMMETRIC HYDROGENATION OF ALKENES USING CHIRAL IRIDIUM COMPLEXES | DSMIP Assets B.V. (NL) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006066863-A1 | ASYMMETRIC HYDROGENATION OF ALKENNES USING CHIRAL IRIDIUM COMPLEXES | DSM IP ASSETS B.V. (NL) | 2006-06-29 | — | — | WO | disclosed |
| US-4160865-A | Asymmetric synthesis | HOFFMANN-LA ROCHE INC. (US) | 1979-07-10 | — | — | US | disclosed |
| US-4151360-A | Optically active amine salts | HOFFMANN-LA ROCHE INC. (US) | 1979-04-24 | — | — | US | disclosed |
| US-4102909-A | Optically active esters and amides | HOFFMANN-LA ROCHE INC. (US) | 1978-07-25 | — | — | US | disclosed |
| US-4094892-A | CLAISEN REARRANGEMENT | HOFFMANN-LA ROCHE INC. (US) | 1978-06-13 | — | — | US | disclosed |
| US-4045475-A | Optically active alcohols and lower esters thereof | HOFFMANN-LA ROCHE INC. (US) | 1977-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039638-A1 | Asymmetric Hydrogenation of Alkennes Using Chiral Iridium Complexes | SQLE, FADS1, FADS2 | BLM 3337/4885LMNA 4536/4885PTPN1 4692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.